Media coverage about Boston Scientific Corporation (NYSE:BSX) has been trending positive this week, according to Accern. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Boston Scientific Corporation earned a news impact score of 0.32 on Accern’s scale. Accern also assigned media stories about the medical equipment provider an impact score of 46.7844091629249 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media stories that may have effected Accern’s rankings:
- Quant Score Keep Boston Scientific (BSX) a Buy (investorplace.com)
- Alluring Stocks: Boston Scientific Corporation, (NYSE: BSX), Knight-Swift Transportation Holdings Inc., (NYSE: KNX … – Stocks In The News (press release) (tradingnewsnow.com)
- Is The Stock Risky? (Beta Analysis) – Boston Scientific Corporation, (NYSE: BSX) – Stock Watch (stocksnewstimes.com)
- Analysts Anticipate Boston Scientific Corporation (BSX) Will Post Quarterly Sales of $2.35 Billion (americanbankingnews.com)
- Boston Scientific Corporation (BSX) Conquer Concerns on Short-Term Commitments – Stock News Stop (stockmarketstop.com)
A number of analysts have issued reports on the company. Royal Bank Of Canada reissued a “buy” rating and issued a $31.00 target price on shares of Boston Scientific Corporation in a research report on Tuesday, November 7th. SunTrust Banks, Inc. set a $34.00 price objective on Boston Scientific Corporation and gave the stock a “buy” rating in a research report on Tuesday, October 31st. Zacks Investment Research lowered Boston Scientific Corporation from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. BMO Capital Markets upped their price objective on Boston Scientific Corporation from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Friday, October 27th. Finally, Canaccord Genuity began coverage on Boston Scientific Corporation in a research report on Tuesday, October 24th. They set a “buy” rating and a $36.00 price objective on the stock. One research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $30.77.
Shares of Boston Scientific Corporation (BSX) traded up $0.09 on Tuesday, hitting $28.35. 3,410,600 shares of the stock traded hands, compared to its average volume of 6,602,495. Boston Scientific Corporation has a twelve month low of $19.67 and a twelve month high of $29.93. The firm has a market capitalization of $38,810.00, a P/E ratio of 23.16, a price-to-earnings-growth ratio of 2.18 and a beta of 0.99. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58.
Boston Scientific Corporation (NYSE:BSX) last announced its earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share for the quarter, hitting the consensus estimate of $0.31. Boston Scientific Corporation had a net margin of 9.55% and a return on equity of 23.60%. The business had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter in the prior year, the firm earned $0.27 earnings per share. The business’s quarterly revenue was up 5.6% compared to the same quarter last year. sell-side analysts forecast that Boston Scientific Corporation will post 1.25 earnings per share for the current fiscal year.
In related news, EVP Timothy A. Pratt sold 10,000 shares of the stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $28.22, for a total transaction of $282,200.00. Following the completion of the transaction, the executive vice president now directly owns 164,681 shares of the company’s stock, valued at $4,647,297.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael P. Phalen sold 15,500 shares of the stock in a transaction dated Tuesday, August 29th. The stock was sold at an average price of $26.87, for a total transaction of $416,485.00. The disclosure for this sale can be found here. Insiders have sold 508,864 shares of company stock valued at $14,581,669 over the last three months. 0.74% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Boston Scientific Corporation (BSX) Given Media Sentiment Rating of 0.32” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://stocknewstimes.com/2017/11/21/boston-scientific-corporation-bsx-given-media-sentiment-rating-of-0-32.html.
Boston Scientific Corporation Company Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.